ClinicalTrials.Veeva

Menu
D

Dr. S. K. Siddha Medicine Professional Corporation | Newmarket, Canada

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Spesolimab
Rocatinlimab
CTP-543
Ruxolitinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 10 total trials

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE)

The coprimary objectives of the study are to:* evaluate the efficacy of rocatinlimab in combination with topical corticosteroid and/or topical calcin...

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab
Locations recently updated

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Enrolling
Atopic Dermatitis
Drug: Rocatinlimab
Other: Placebo
Locations recently updated

This study is open to people with hidradenitis suppurativa (HS) who have completed another study with spesolimab (study 1368-0098 (NCT05819398) or st...

Enrolling
Hidradenitis Suppurativa (HS)
Drug: Spesolimab

The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in a...

Active, not recruiting
Alopecia Areata
Drug: CTP-543
Locations recently updated

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine calle...

Enrolling
Hidradenitis Suppurativa
Drug: Placebo matching Spesolimab Formulation 1
Drug: Placebo matching Spesolimab Formulation 2

Trial sponsors

Boehringer Ingelheim logo
Amgen logo
Concert Pharmaceuticals logo
Incyte logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems